These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 469242)

  • 1. Effect of specific phospholipids on the antibody-complement-mediated killing of nucleated cells.
    Ohanian SH; Schlager SI; Yamazaki M; Ishida B
    J Immunol; 1979 Sep; 123(3):1014-9. PubMed ID: 469242
    [No Abstract]   [Full Text] [Related]  

  • 2. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense.
    Ohanian SH; Schlager SI
    Crit Rev Immunol; 1981 Jan; 1(3):165-209. PubMed ID: 6174273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma membrane and intracellular lipid synthesis in tumor cells rendered resistant to humoral immune killing after treatment with hormones.
    Schlager SI; Ohanian SH
    J Natl Cancer Inst; 1980 Apr; 64(4):943-50. PubMed ID: 6988626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lipids, structural precursors of lipids and fatty acids on complement-mediated killing of antibody-sensitized nucleated cells.
    Ohanian SH; Schlager SI; Saha S
    Mol Immunol; 1982 Apr; 19(4):535-42. PubMed ID: 7087963
    [No Abstract]   [Full Text] [Related]  

  • 5. Homologous species restriction of the complement-mediated killing of nucleated cells.
    Yamamoto H; Blaas P; Nicholson-Weller A; Hänsch GM
    Immunology; 1990 Aug; 70(4):422-6. PubMed ID: 1697561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between the intracellular cyclic adenosine 3':5'-monophosphate level of tumor cells and their sensitivity to killing by antibody and complement.
    Lo TN; Boyle MD
    Cancer Res; 1979 Aug; 39(8):3156-62. PubMed ID: 222445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between the ability of tumor cells to incorporate specific fatty acids and their sensitivity to killing by a specific antibody plus guinea pig complement.
    Schlager SI; Ohanian SH; Borsos T
    J Natl Cancer Inst; 1978 Sep; 61(3):931-4. PubMed ID: 278869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophil-mediated killing of schistosomula of Schistosoma mansoni in vitro: synergistic effect of antibody and complement.
    McLaren DJ; Ramalho-Pinto FJ
    J Immunol; 1979 Oct; 123(4):1431-8. PubMed ID: 479590
    [No Abstract]   [Full Text] [Related]  

  • 9. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of cytotoxicity of islet cell surface antibodies in vivo despite complement-mediated cytotoxic effects to islet cells in vitro.
    Kohnert KD; Hehmke B; Fält K; Ziegler M
    Biomed Biochim Acta; 1984; 43(5):663-73. PubMed ID: 6206850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell growth-dependent variation in the sensitivity of human and mouse tumor cells to complement-mediated killing.
    Ohanian SH; Yamazaki M; Schlager SI; Faibisch M
    Cancer Res; 1983 Feb; 43(2):491-5. PubMed ID: 6401218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-mediated killing of myeloma tumour cells: differences in susceptibility to lysis by antibodies and complement are independent of antigen expression and antibody binding.
    Celis B; Celis E
    Immunology; 1983 Jun; 49(2):321-8. PubMed ID: 6343234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
    Kinouchi T; Bander NH; Kotake T
    J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies which react with lymphocyte-lysed target cells and which cross-react with complement-lysed ghosts.
    Ward RH; Lachmann PJ
    Immunology; 1985 Sep; 56(1):179-88. PubMed ID: 4043993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative comparison of techniques used to measure complement-mediated cytotoxicity of nucleated cells.
    Detrick-Hooks B; Borsos T; Rapp HJ
    J Immunol; 1975 Jan; 114(1 Pt 2):287-90. PubMed ID: 1117130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. I. Evidence for the existence of an intermediate, T.
    Boyle MD; Ohanian SH; Borsos T
    J Immunol; 1976 May; 116(5):1272-5. PubMed ID: 178793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of hormone-induced tumor cell resistance to killing by antibody and complement.
    Schlager SI; Ohanian SH; Borsos T
    Cancer Res; 1977 Mar; 37(3):765-70. PubMed ID: 189914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolysis of Sendai virus-infected guinea-pig cells by homologous complement.
    Okada H; Tanaka H; Okada N
    Immunology; 1983 May; 49(1):29-35. PubMed ID: 6301976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New monoclonal antibodies specific for the guinea pig line 10 hepatocarcinoma.
    Kataoka T; Chiba J; Ohnuki T; Nemoto K; Tokunaga T
    Jpn J Cancer Res; 1987 Sep; 78(9):960-7. PubMed ID: 3117752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of the synthesis and release of lipids in tumor cells under attack by antibody and C.
    Schlager SI; Ohanian SH; Borsos T
    J Immunol; 1978 Mar; 120(3):895-901. PubMed ID: 632591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.